Efficacy and safety of a 4-year combination therapy of growth hormone and gonadotropin-releasing hormone analogue in pubertal girls with short predicted adult height.

Autor:	Dotremont H; Department of Pediatrics, University Hospital Antwerp, Edegem, Belgium.; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Edegem, Belgium., France A; Department of Pediatrics, University Hospital Antwerp, Edegem, Belgium.; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Edegem, Belgium., Heinrichs C; Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium., Tenoutasse S; Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium., Brachet C; Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium., Cools M; Department of Pediatric Endocrinology, Department of Internal Medicine and Pediatrics, Ghent University, Ghent University Hospital, Ghent, Belgium., De Waele K; Department of Pediatric Endocrinology, Department of Internal Medicine and Pediatrics, Ghent University, Ghent University Hospital, Ghent, Belgium., Massa G; Department of Pediatrics, Jessa Hospital, Hasselt, Belgium., Lebrethon MC; Department of Pediatrics, University Hospital of Liège, Liège, Belgium., Gies I; Department of Pediatric Endocrinology, University Hospital Brussels, Brussels, Belgium., Van Besien J; Department of Pediatric Endocrinology, University Hospital Brussels, Brussels, Belgium., Derycke C; Belgian Society for Pediatric Endocrinology and Diabetes (BESPEED), Brussels, Belgium., Ziraldo M; Unité d 'Endocrinologie Pédiatrique Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium., De Schepper J; Department of Pediatric Endocrinology, Department of Internal Medicine and Pediatrics, Ghent University, Ghent University Hospital, Ghent, Belgium.; Department of Pediatric Endocrinology, University Hospital Brussels, Brussels, Belgium., Beauloye V; Unité d 'Endocrinologie Pédiatrique Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium., Verhulst S; Department of Pediatrics, University Hospital Antwerp, Edegem, Belgium.; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Edegem, Belgium., Rooman R; PendoCon, Putte, Belgium., den Brinker M; Department of Pediatrics, University Hospital Antwerp, Edegem, Belgium.; Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Edegem, Belgium.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Mar 17; Vol. 14, pp. 1113750. Date of Electronic Publication: 2023 Mar 17 (Print Publication: 2023).
DOI:	10.3389/fendo.2023.1113750
Abstrakt:	Objectives: To improve adult height in pubertal girls with a poor height prediction, treatment with growth hormone (GH) can be used in combination with a gonadotropin releasing hormone agonist (GnRHa), to delay closure of the growth plates. However, there are few studies to support this practice, and they show conflicting results. The objective of this trial is to assess the safety and efficacy of this combination treatment in early pubertal girls with a short predicted height, in comparison with matched controls. Design Patients and Methods: We designed an open-label, multicenter, interventional case-control study. Early pubertal girls with predicted adult height (PAH) below -2.5 SDS, were recruited in tertiary care centers in Belgium. They were treated for four years with GH and GnRHa. The girls were followed until adult height (AH) was reached. AH vs PAH, AH vs Height at start, and AH vs Target Height (TH) were evaluated, as well as safety parameters. Control data were assembled from historical patient files or from patients who preferred not to participate in the study. Results: Sixteen girls with mean age ( ± SD) at start of 11.0 years (± 1.3) completed the study protocol and follow-up. Their mean height ( ± SD) increased from 131.3 ± 4.1 cm (-2.3 ± 0.7 SDS) at start of treatment to 159.8 ± 4.7 cm (-1.1 ± 0.7 SDS) at AH. In matched controls, height increased from 132.3 ± 4.2 cm (-2.4 ± 0.5 SDS) to 153.2 ± 3.4 cm (-2.1 ± 0.6 SDS) (p<0.001). AH surpassed initial PAH by 12.0 ± 2.6 cm in treated girls; and by 4.2 ± 3.6 cm in the controls (p<0.001). Most treated girls reached normal adult height (>-2SD) (87.5%) and 68.7% reached or superseded the target height (TH), which was the case in only a minority of the controls (37.5% and 6.2%, respectively) (p= 0.003 and 0.001). A serious adverse event possibly related to the treatment, was a fracture of the metatarsals. Conclusion: A four-year GH/GnRHa treatment in early pubertal girls with a poor PAH seems safe and results in a clinically relevant and statistically significant increase in AH compared with matched historical controls. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT00840944. Competing Interests: Author RR is the owner of the company PendoCon. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Dotremont, France, Heinrichs, Tenoutasse, Brachet, Cools, De Waele, Massa, Lebrethon, Gies, Van Besien, Derycke, Ziraldo, De Schepper, Beauloye, Verhulst, Rooman and den Brinker.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu